Bevacizumab 25mg/ml Injection (Bevacizumab 25mg/ml)

Home > Bevacizumab 25mg/ml Injection (Bevacizumab 25mg/ml)

27 Apr Bevacizumab 25mg/ml Injection (Bevacizumab 25mg/ml)

Posted at 13:33h in by

Company name & Address: Registration number Batch number(s) Expiry date Pack size First distributed Re-call Classification Recall date
Eurolab ASU, a division of Eurolab (Pty) Ltd, Units 5&6, K101 Business Park, Capital Hill Commercial Estate, Cnr Le Roux Avenue and K101 Old Pretoria, Main Road, Halfway House, Midrand, 1685  

N/A

  

BEV0300622

  

11.April.2025

  

50ul

  

27.February.2025

  

Class II Type C

  

16.May.2025

 

Brief description of the problem (reason for recall)

This recall is initiated due to contravention of Section 14 of the Medicines and Related Substances Act, 101 of 1965, as amended and contravention to the license conditions.

 

Advice for health professionals and distributors

We request that you refrain from selling the affected batches of Bevacizumab. Eurolab ASU will make the necessary arrangements for collection of all your stock currently on hand.

 

Proposed action taken and its urgency: A SAHPRA approved recall letter was distributed to all distribution points and the recall process was initiated.

 

Reporting side effects

Public and healthcare professionals are encouraged to report any side effects after using a health product or after immunisation by using the Med Safety App. Your report will contribute to our monitoring of these health products.

Download latest version
Version: 1
Date Updated: 16/05/2025
File Type: www
Category: Product Recall
Unit: General ECTD & human medicines, Regulatory Compliance